← Back to Search

Atezolizumab + Bevacizumab vs Radiation Therapy for Liver Cancer (ADVANCE HCC Trial)

Phase 2
Recruiting
Led By Brandon Meyers, MD
Research Sponsored by Ontario Clinical Oncology Group (OCOG)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years
PVTT involving the portal vein branches: Vp1-Vp3 (Japanese Classification for HCC with PVTT, see Appendix II)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

ADVANCE HCC Trial Summary

This trial is testing two different treatments for people with a certain type of liver cancer. The first group of people will get a drug called Atezolizumab, and the second group will get a different drug called Bevacizumab. The trial will compare how well each treatment works.

Who is the study for?
Adults over 18 with a specific liver cancer (HCC) and blood clots in the portal vein, without spread to other areas or severe liver damage. They must not have had previous HCC treatments or certain other health conditions like recent serious infections, bleeding issues, significant heart disease, autoimmune diseases, or be pregnant.Check my eligibility
What is being tested?
The trial is testing two pre-surgery treatments for liver cancer: Atezolizumab/Bevacizumab versus radiation therapy (SBRT). It's a Phase II study where patients are randomly assigned to one of these experimental groups. The effectiveness will be measured by tumor response before surgery.See study design
What are the potential side effects?
Possible side effects include allergic reactions to treatment components, increased risk of infection due to immune system suppression, potential bleeding complications from Bevacizumab and general side effects like fatigue and digestive issues.

ADVANCE HCC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
My liver cancer has spread to the main branches of the portal vein.
Select...
My liver functions well despite my illness.
Select...
My liver cancer is confirmed by biopsy and hasn't spread.

ADVANCE HCC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hepatectomy
Secondary outcome measures
Postoperative complications
Response rate
Survival
+3 more

ADVANCE HCC Trial Design

2Treatment groups
Experimental Treatment
Group I: Neoadjuvant SBRTExperimental Treatment1 Intervention
• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
Group II: Neoadjuvant Atezolizumab/BevacizumabExperimental Treatment1 Intervention
• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles

Find a Location

Who is running the clinical trial?

Ontario Clinical Oncology Group (OCOG)Lead Sponsor
62 Previous Clinical Trials
41,827 Total Patients Enrolled
Hoffmann-La RocheIndustry Sponsor
2,427 Previous Clinical Trials
1,089,081 Total Patients Enrolled
4 Trials studying Liver Cancer
156 Patients Enrolled for Liver Cancer
Brandon Meyers, MDPrincipal Investigatorprinciple investigator

Media Library

Neoadjuvant Clinical Trial Eligibility Overview. Trial Name: NCT05137899 — Phase 2
Liver Cancer Research Study Groups: Neoadjuvant Atezolizumab/Bevacizumab, Neoadjuvant SBRT
Liver Cancer Clinical Trial 2023: Neoadjuvant Highlights & Side Effects. Trial Name: NCT05137899 — Phase 2
Neoadjuvant 2023 Treatment Timeline for Medical Study. Trial Name: NCT05137899 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the geographic distribution of this research endeavor?

"This medical trial is currently taking place across 12 sites, including the Ottawa Regional Cancer Centre in Ottawa, McGill Cedars Cancer Centre in Montréal and Tom Baker Cancer Centre in Calgary."

Answered by AI

To what extent can Neoadjuvant treatment be detrimental to patient health?

"Our team at Power assessed Neoadjuvant's safety to be a 2, as this is still in the second phase of clinical trials and there has not been sufficient evidence gathered on its efficacy."

Answered by AI

Is there a recruitment process ongoing for this investigation?

"Affirmative. According to clinicaltrials.gov, this trial is actively seeking 70 participants from 9 diverse locations. The study was initially made available on October 18th of 2022 and the entry has been modified since that date."

Answered by AI

What is the upper limit of participants involved in this investigation?

"This clinical trial necessitates the enrollment of 70 suitable patients from multiple sites, including Ottawa Regional Cancer Centre and McGill Cedars Cancer Centre."

Answered by AI
~43 spots leftby Jun 2026